Cargando…

Epidermal Permeability Barrier in the Treatment of Keratosis Pilaris

Objectives. To evaluate and compare the efficacy, safety, hydrating properties, and tolerability of 10% lactic acid (LA) and 5% salicylic acid (SA) in the therapy of keratosis pilaris (KP). Material and Method. Patients with KP were randomized for treatment with either 10% LA or 5% SA creams being a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kootiratrakarn, Tanawatt, Kampirapap, Kowit, Chunhasewee, Chakkrapong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354723/
https://www.ncbi.nlm.nih.gov/pubmed/25802513
http://dx.doi.org/10.1155/2015/205012
_version_ 1782360786359812096
author Kootiratrakarn, Tanawatt
Kampirapap, Kowit
Chunhasewee, Chakkrapong
author_facet Kootiratrakarn, Tanawatt
Kampirapap, Kowit
Chunhasewee, Chakkrapong
author_sort Kootiratrakarn, Tanawatt
collection PubMed
description Objectives. To evaluate and compare the efficacy, safety, hydrating properties, and tolerability of 10% lactic acid (LA) and 5% salicylic acid (SA) in the therapy of keratosis pilaris (KP). Material and Method. Patients with KP were randomized for treatment with either 10% LA or 5% SA creams being applied twice daily for 3 months. The patients were clinically assessed at baseline and after 4, 8, and 12 weeks of treatment and 4 weeks after treatment. The functional properties of the stratum corneum (SC) were determined before treatment, 12 weeks, and follow-up phase by high-frequency conductance and transepidermal water loss (TEWL). Results. At the end of the trial, the mean reduction of the lesions from baseline was statistically significant for 10% LA (66%) and 5% SA (52%). During the treatment, higher conductance values were found on both group and this improvement was maintained until the follow up period. No significant differences in transepidermal water loss were observed after treatment. The adverse effects were limited to mild irritation localized on the skin without systemic side effect. Conclusion. The study demonstrated that 10% LA and 5% SA are beneficial to treat KP with the significantly clearance and marked improvement as by instrumental evaluation.
format Online
Article
Text
id pubmed-4354723
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-43547232015-03-23 Epidermal Permeability Barrier in the Treatment of Keratosis Pilaris Kootiratrakarn, Tanawatt Kampirapap, Kowit Chunhasewee, Chakkrapong Dermatol Res Pract Clinical Study Objectives. To evaluate and compare the efficacy, safety, hydrating properties, and tolerability of 10% lactic acid (LA) and 5% salicylic acid (SA) in the therapy of keratosis pilaris (KP). Material and Method. Patients with KP were randomized for treatment with either 10% LA or 5% SA creams being applied twice daily for 3 months. The patients were clinically assessed at baseline and after 4, 8, and 12 weeks of treatment and 4 weeks after treatment. The functional properties of the stratum corneum (SC) were determined before treatment, 12 weeks, and follow-up phase by high-frequency conductance and transepidermal water loss (TEWL). Results. At the end of the trial, the mean reduction of the lesions from baseline was statistically significant for 10% LA (66%) and 5% SA (52%). During the treatment, higher conductance values were found on both group and this improvement was maintained until the follow up period. No significant differences in transepidermal water loss were observed after treatment. The adverse effects were limited to mild irritation localized on the skin without systemic side effect. Conclusion. The study demonstrated that 10% LA and 5% SA are beneficial to treat KP with the significantly clearance and marked improvement as by instrumental evaluation. Hindawi Publishing Corporation 2015 2015-02-24 /pmc/articles/PMC4354723/ /pubmed/25802513 http://dx.doi.org/10.1155/2015/205012 Text en Copyright © 2015 Tanawatt Kootiratrakarn et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Kootiratrakarn, Tanawatt
Kampirapap, Kowit
Chunhasewee, Chakkrapong
Epidermal Permeability Barrier in the Treatment of Keratosis Pilaris
title Epidermal Permeability Barrier in the Treatment of Keratosis Pilaris
title_full Epidermal Permeability Barrier in the Treatment of Keratosis Pilaris
title_fullStr Epidermal Permeability Barrier in the Treatment of Keratosis Pilaris
title_full_unstemmed Epidermal Permeability Barrier in the Treatment of Keratosis Pilaris
title_short Epidermal Permeability Barrier in the Treatment of Keratosis Pilaris
title_sort epidermal permeability barrier in the treatment of keratosis pilaris
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354723/
https://www.ncbi.nlm.nih.gov/pubmed/25802513
http://dx.doi.org/10.1155/2015/205012
work_keys_str_mv AT kootiratrakarntanawatt epidermalpermeabilitybarrierinthetreatmentofkeratosispilaris
AT kampirapapkowit epidermalpermeabilitybarrierinthetreatmentofkeratosispilaris
AT chunhaseweechakkrapong epidermalpermeabilitybarrierinthetreatmentofkeratosispilaris